BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24852275)

  • 1. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents.
    Wu LT; Jiang Z; Shen JJ; Yi H; Zhan YC; Sha MQ; Wang Z; Xue ST; Li ZR
    Eur J Med Chem; 2016 May; 114():328-36. PubMed ID: 27017265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.
    Shen QK; Deng H; Wang SB; Tian YS; Quan ZS
    Eur J Med Chem; 2019 Jul; 173():15-31. PubMed ID: 30981113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
    Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
    Uesato S; Matsuura Y; Matsue S; Sumiyoshi T; Hirata Y; Takemoto S; Kawaratani Y; Yamai Y; Ishida K; Sasaki T; Enari M
    Bioorg Med Chem; 2016 Apr; 24(8):1919-26. PubMed ID: 27010502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
    Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
    Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
    Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
    Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
    Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
    Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
    Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
    Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
    Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
    Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
    Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
    J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and
    Alimujiang Y; Maimaiti A; Ablise M; Yang Z; Liu Z; Wang Y; Mutalipu Z; Yan T
    Anticancer Agents Med Chem; 2024; 24(6):423-435. PubMed ID: 38204258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
    J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.